Our programs are designed for small cap life sciences issuers who seek a closer relationship between their intrinsic and public market values.
 |
| CLICK TO DOWNLOAD |
Our approach is built on more than 25 years of working with some of the industry’s most gifted entrepreneurs as they guided the early days of companies like Celgene, Calgene, Medarex, Texas Biotechnology, Axsome, TG Therapeutics, Keryx, Fortress Biotech, Quidel, Elan, Urigen, Galapagos, Stemcell, Crucell, and many others -- all bearing witness to the value proposition of translating science and opportunity to a level of understanding, then presenting it in ways and in places that matter most to risk-tolerant investors.
In the process we gained exceptional insights into how investors view risk investments in life sciences and the message elements that are most effective in drawing their attention. Tailored programs involve a mix of outreach tools that include media, digital communications, analyst reports, industry perspectives, corporate profiles, teach-ins, and non-deal road shows.
We actively communicate with roughly 2,600 financial advisors at local, regional and national wire houses, more than 200 family offices and 10,000 medically degreed high net worth investors.
As a class, these investors are the ones that generally set share price and account for routine daily liquidity of small cap issuers. That is why we focus on them: their investment strategies enable them to build positions in small cap companies in the public market before the time when market caps or liquidity meet the criteria of most institutional investors.
Ph: 212 926-1733 Email: info@redingtoninc.com
